Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a fellow of the AACR Academy. He is among 11 new fellows announced by the American Association for Cancer Research, the largest international cancer organization dedicated to cancer […]
News: Breast CancerNext Page »
The stands inside Memorial Gymnasium are expected to resemble a sea of pink as fans don pink attire for the Vanderbilt Commodores Women’s Basketball game Sunday, Feb. 8, at noon. The Commodores will play the University of Kentucky Wildcats during the annual Pink Out! Game, which is designed to raise awareness of breast cancer and […]
Breast cancer remains the most common type of cancer in females, with survival rates decreasing sharply for those with distant metastases. MMP2, a type of enzyme that degrades the extracellular matrix, has previously been implicated in the development of distant tumor metastases, but without a clearly defined role. In the Journal of Pathology, Barbara Fingleton, […]
Two therapies already in clinical development as single agents may work in combination to treat many subtypes of melanoma, a recent study suggests.
A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy. The study was published online in the Journal of Clinical Investigation. Luis Schwarz, M.D., and Emily Fox, Ph.D., served as co-first authors of the study, led by senior author Carlos […]
Far more breast cancer patients are choosing to undergo mastectomy, including removal of both breasts, instead of choosing breast conservation surgery even when they have early stage disease that is confined to one breast, a Vanderbilt study shows.
A new study explaining the cellular activity that leads to breast tumor metastasis among women who have recently given birth may offer new treatment direction for postpartum breast cancer.
Three Vanderbilt-Ingram Cancer Center (VICC) investigators have been awarded breast cancer research grants totaling $830,000 from the Susan G. Komen organization.
A new Vanderbilt University School of Nursing (VUSN) study may lead to earlier detection and better outcomes for the 20-30 percent of breast cancer patients with lymphedema, the painful and stigmatizing arm swelling that often results from treatment.
Targeting a cytokine pathway may offer a way to inhibit breast cancer cell survival and metastasis, study suggests.